Clinical Trials Browser

Phase 1/2 × Pharmacogenomic Variants × 90 days × Clear all

NCT03582124 2026-02-10

Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

Phase 1/2 Recruiting

Lung Neoplasms

NCT03225664 2026-01-16

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms